FDA Rejects Request To Expand Nuplazid Use For Symptoms of Dementia-Related Psychosis
Federal health regulators have rejected an application filed by Acadia Pharmaceuticals to expand the use of its blockbuster antipsychotic drug, Nuplazid, highlighting concerns that the medication may not be effective…